Human Bites in Emergency Medicine

Back

Background

Human bite wounds have a notorious reputation, which is mostly based on one injury, the closed-fist injury. Human bites in other areas pose no greater risk than animal bites. Three general types of injuries can lead to complications: (1) closed-fist injury, (2) chomping injury to the finger, and (3) puncture-type wounds about the head caused by clashing with a tooth. Otherwise, the general principles of contaminated wound management apply to human bite wounds.

For more information, see Medscape's Wound Management Resource Center.

Pathophysiology

In a closed-fist injury, forces sufficient to break the skin from striking an opponent's tooth often inoculate the extensor tendon and its sheath. As the hand is flexed at the time of impact, the bacterial load is transferred caudally when the hand is opened and the tendon slides back to its relaxed state. Resulting contamination cannot be removed readily through normal cleansing and irrigation.

When a finger is bitten, such as in a chomping-type injury, tendons and their overlying sheaths are in close proximity to the skin. The wound may appear to be a minor abrasion-type injury, but careful inspection is required to rule out deep injury.

When a tooth strikes the head, even a deep puncture wound may appear innocuous. Deep, subgaleal, bacterial contamination is possible. This is especially true in young children who have relatively thin soft scalp and forehead tissue.

Epidemiology

Frequency

United States

Exact incidence of human bite wounds is unknown, and many cases do not come to medical attention. Institutionalized patients with poor impulse control create a high-risk environment for human bite wounds. Lesch-Nyhan syndrome is an uncommon disorder that includes self-mutilation through biting.

International

In a 4-year retrospective review in the United Kingdom, 421 (13%) human bites were identified out of 3136 case notes. The majority of those bitten were young males, with 44% of the males aged 16-25 years. The male-to-female ratio was 3:1.[1]

Mortality/Morbidity

Sex

Age

History

Physical

Causes

Laboratory Studies

Imaging Studies

Procedures

Prehospital Care

Emergency Department Care

The acute, noninfected human bite

The infected human bite wound

Other considerations

Consultations

Medication Summary

The only drug therapy of significance in human bites is antibiotic treatment. Bacterial flora include that of the mouth and skin. Theoretically, penicillin treats oral pathogens and may suffice for prophylactic treatment as Staphylococcus species probably only infect bite wounds secondarily.

Once a human bite is infected, beta-lactamase–producing staphylococci must be addressed. Eikenella corrodens may not be covered by first-generation cephalosporins. Additionally, Eikenella species are resistant to clindamycin, penicillinase-resistant semisynthetic penicillins, and metronidazole. A broad-spectrum antibiotic, rather than combination therapy, is the usual choice for infected bite wounds. An in vitro study of 50 infected human bites by Talan et al indicated that amoxicillin-clavulanic acid and moxifloxacin demonstrated excellent activity against common isolates.[8]

Amoxicillin/clavulanate (Augmentin)

Clinical Context:  Drug combination that extends antibiotic spectrum of this penicillin to include bacteria normally resistant to beta-lactam antibiotics. DOC for noninfected human bite wounds. Dosing is based on amoxicillin component. Indicated for skin and skin structure infections caused by beta-lactamase-producing strains of Staphylococcus aureus.

Ampicillin/sulbactam sodium (Unasyn)

Clinical Context:  Drug combination that uses beta-lactamase inhibitor with ampicillin; covers skin, enteric flora, and anaerobes. DOC for infected bites.

Cefoxitin (Mefoxin)

Clinical Context:  Alternative drug for infected bites; second-generation cephalosporin indicated for management of infections caused by susceptible gram-positive cocci and gram-negative rods. Many infections that are caused by gram-negative bacteria and are resistant to some cephalosporins and penicillins respond to cefoxitin.

Moxifloxacin (Avelox)

Clinical Context:  Inhibits the A subunits of DNA gyrase, resulting in inhibition of bacterial DNA replication and transcription.

Class Summary

Therapy must cover all likely pathogens in the context of the clinical setting.

Tetanus immune globulin (TIG)

Clinical Context:  Used for passive immunization of any person with a wound that may be contaminated with tetanus spores.

Class Summary

These agents are used to immunize patients against tetanus.

Further Outpatient Care

Complications

Prognosis

Author

Jeffrey Barrett, MD, Assistant Professor, Department of Emergency Medicine, Temple University School of Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Clifford S Spanierman, MD, Consulting Staff, Departments of Emergency Medicine and Pediatrics, Lutheran General Hospital of Oak Brook, Advocate Health System

Disclosure: Nothing to disclose.

Robert M McNamara, MD, FAAEM, Chair and Professor, Department of Emergency Medicine, Temple University School of Medicine

Disclosure: Nothing to disclose.

Specialty Editors

Samuel M Keim, MD, Associate Professor, Department of Emergency Medicine, University of Arizona College of Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

James Steven Walker, DO, MS, Clinical Professor of Surgery, Department of Surgery, University of Oklahoma College of Medicine

Disclosure: Nothing to disclose.

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center

Disclosure: Nothing to disclose.

Chief Editor

Rick Kulkarni, MD, Attending Physician, Department of Emergency Medicine, Cambridge Health Alliance, Division of Emergency Medicine, Harvard Medical School

Disclosure: WebMD Salary Employment

References

  1. Harrison M. A 4-year review of human bite injuries presenting to emergency medicine and proposed evidence-based guidelines. Injury. Jan 31 2009;[View Abstract]
  2. Vidmar L, Poljak M, Tomazic J, Seme K, Klavs I. Transmission of HIV-1 by human bite. Lancet. 1996;347:1762. [View Abstract]
  3. Zubowicz VN, Gravier M. Management of early human bites of the hand: a prospective randomized study. Plast Reconstr Surg. Jul 1991;88(1):111-4. [View Abstract]
  4. Broder J, Jerrard D, Olshaker J, Witting M. Low risk of infection in selected human bites treated without antibiotics. Am J Emerg Med. Jan 2004;22(1):10-3. [View Abstract]
  5. Baker MD, Moore SE. Human bites in children. A six-year experience. Am J Dis Child. Dec 1987;141(12):1285-90. [View Abstract]
  6. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. Nov 15 2005;41(10):1373-406. [View Abstract]
  7. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep. Jan 21 2005;54(RR-2):1-20. [View Abstract]
  8. Talan DA, Abrahamian FM, Moran GJ, et al. Clinical presentation and bacteriologic analysis of infected human bites in patients presenting to emergency departments. Clin Infect Dis. Dec 1 2003;37(11):1481-9. [View Abstract]
  9. Bunzli WF, Wright DH, Hoang AT, et al. Current management of human bites. Pharmacotherapy. Mar-Apr 1998;18(2):227-34. [View Abstract]
  10. Chen E, Hornig S, Shepherd SM, Hollander JE. Primary closure of mammalian bites. Acad Emerg Med. Feb 2000;7(2):157-61. [View Abstract]
  11. Donkor P, Bankas DO. A study of primary closure of human bite injuries to the face. J Oral Maxillofac Surg. May 1997;55(5):479-81; discussion 481-2. [View Abstract]
  12. Gilbert DN, Moellering RC, Sande MA. Human bites. In: The Sanford Guide to Antimicrobial Therapy. 30th ed. Antimicrobial Therapy Inc; 2000:37.
  13. Kelly IP, Cunney RJ, Smyth EG, Colville J. The management of human bite injuries of the hand. Injury. Sep 1996;27(7):481-4. [View Abstract]
  14. Lindsey D, Christopher M, Hollenbach J, et al. Natural course of the human bite wound: incidence of infection and complications in 434 bites and 803 lacerations in the same group of patients. J Trauma. Jan 1987;27(1):45-8. [View Abstract]
  15. Miura I, Ohshima A, Takahashi N, et al. A new non-random chromosomal translocation t(3;6)(q27;p21.3) associated with BCL6 rearrangement in two patients with non-Hodgkin's lymphoma. Int J Hematol. Oct 1996;64(3-4):249-56. [View Abstract]
  16. Pretty IA, Anderson GS, Sweet DJ. Human bites and the risk of human immunodeficiency virus transmission. Am J Forensic Med Pathol. Sep 1999;20(3):232-9. [View Abstract]
  17. Schweich P, Fleisher G. Human bites in children. Pediatr Emerg Care. Jun 1985;1(2):51-3. [View Abstract]
  18. Smith PF, Meadowcroft AM, May DB. Treating mammalian bite wounds. J Clin Pharm Ther. Apr 2000;25(2):85-99. [View Abstract]
  19. Turner TW. Evidence-based emergency medicine/systematic review abstract. Do mammalian bites require antibiotic prophylaxis?. Ann Emerg Med. Sep 2004;44(3):274-6. [View Abstract]